PharmaceuticalsHouston, TexasAnnouncement date · Aug 10, 2026

Generation Park Multi-Modal Manufacturing Campus

See all projects by Bristol Myers Squibb →

Bristol Myers Squibb's approximately $2.3 billion, roughly 600,000-square-foot modular and multi-modal manufacturing campus at Generation Park in Houston, Texas. The campus is designed to produce multiple medicine types — small molecules, biologics and antibody-drug conjugates — supporting drug product and finished-goods manufacturing from late development through launch, with a modular architecture BMS can reconfigure as its pipeline evolves. BMS announced the site selection on August 10, 2026 and says the campus will create nearly 500 skilled jobs initially, spanning operations technicians, production specialists, maintenance and engineering, quality control and assurance, and site leadership; AFT records 500 permanent jobs against that "nearly 500" wording. No construction start or opening date has been disclosed, so the record stays in Planning without an assigned date. Explicitly excluded to prevent double counting and non-qualifying inflation: the approximately 2,000 construction and other indirect jobs expected between 2027 and 2030; BMS's broader $40 billion five-year U.S. commitment, which spans research and development, technology and domestic manufacturing rather than this facility; BMS's approximately $10 billion 2025 research-and-development spend; industry-wide research and employment-multiplier claims; and BMS's existing Texas contract-manufacturing and clinical-trial-site relationships, which carry no new capital or permanent operating jobs. Eli Lilly's separately tracked active-pharmaceutical-ingredient facility sits in the same 4,300-acre Generation Park development but is an unrelated project by a different company.

Investment
$2.30B
Permanent jobs announced
500
Status
Planning
Opening timeline
Not yet announced
Why this project qualifies

With $2.3 billion in facility-specific investment and 500 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Bristol Myers Squibb
Industry
Pharmaceuticals
Location
Houston, Texas
Investment
$2.30B
Permanent jobs announced
500
Status
Planning
Announced
Aug 10, 2026
Opening timeline
Not yet announced
Added to tracker
Sep 1, 2026
Sources

Official references

Related

Other projects to know

In Texas
Across Pharmaceuticals
Back to the tracker/projects/bristol-myers-squibb-generation-park-houston